Equities research analysts expect Jounce Therapeutics, Inc. (NASDAQ:JNCE) to post earnings per share of ($0.15) for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Jounce Therapeutics’ earnings. The lowest EPS estimate is ($0.23) and the highest is ($0.09). The business is scheduled to announce its next quarterly earnings results on Tuesday, August 8th.
On average, analysts expect that Jounce Therapeutics will report full-year earnings of ($0.75) per share for the current fiscal year, with EPS estimates ranging from ($1.03) to ($0.58). For the next year, analysts expect that the company will post earnings of ($1.39) per share, with EPS estimates ranging from ($1.47) to ($1.33). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Jounce Therapeutics.
Jounce Therapeutics (NASDAQ:JNCE) last posted its quarterly earnings data on Tuesday, May 9th. The company reported ($0.02) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.07. The firm had revenue of $20.30 million for the quarter, compared to the consensus estimate of $19.71 million. The firm’s revenue for the quarter was up 202900.0% on a year-over-year basis.
A number of equities analysts have recently issued reports on JNCE shares. Cowen and Company reiterated a “buy” rating on shares of Jounce Therapeutics in a research note on Friday, June 9th. Zacks Investment Research downgraded shares of Jounce Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 12th. J P Morgan Chase & Co started coverage on shares of Jounce Therapeutics in a research note on Tuesday, February 21st. They set an “overweight” rating and a $28.00 price objective on the stock. Robert W. Baird started coverage on shares of Jounce Therapeutics in a research note on Tuesday, February 21st. They set an “outperform” rating and a $30.00 price objective on the stock. Finally, Wells Fargo & Company started coverage on shares of Jounce Therapeutics in a research note on Tuesday, February 21st. They set an “outperform” rating on the stock. They noted that the move was a valuation call. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $28.67.
Several institutional investors have recently added to or reduced their stakes in JNCE. FMR LLC acquired a new position in Jounce Therapeutics during the first quarter worth about $82,387,000. Wellington Management Group LLP acquired a new position in Jounce Therapeutics during the first quarter worth about $34,814,000. Redmile Group LLC acquired a new position in Jounce Therapeutics during the first quarter worth about $22,523,000. Pharmstandard International S.A. acquired a new position in Jounce Therapeutics during the first quarter worth about $14,559,000. Finally, Omega Fund Management LLC acquired a new position in Jounce Therapeutics during the first quarter worth about $12,747,000. Hedge funds and other institutional investors own 39.35% of the company’s stock.
Jounce Therapeutics (NASDAQ:JNCE) traded down 4.32% during mid-day trading on Tuesday, reaching $15.50. The company’s stock had a trading volume of 198,646 shares. The stock’s market cap is $498.08 million. The firm’s 50 day moving average is $22.24 and its 200-day moving average is $21.92. Jounce Therapeutics has a one year low of $15.13 and a one year high of $29.29.
COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Anticipate Jounce Therapeutics, Inc. (JNCE) to Announce -$0.15 Earnings Per Share” was originally reported by WKRB News and is the property of of WKRB News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.wkrb13.com/markets/2228992/zacks-analysts-anticipate-jounce-therapeutics-inc-jnce-to-announce-0-15-earnings-per-share.html.
About Jounce Therapeutics
Jounce Therapeutics, Inc is a clinical-stage immunotherapy company. The Company is engaged in developing therapies that enable the immune system to attack tumors. Through the use of its Translational Science Platform, the Company first focuses on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2228992/zacks-analysts-anticipate-jounce-therapeutics-inc-jnce-to-announce-0-15-earnings-per-share.html
Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.